标题 |
Anti-Pd-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal. 2023 EHA. 4. Jae-Cheol Jo, Misung Kim, Yunsuk Choi, et al. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type
抗Pd-1抗体(Tislelizumab)联合脱乙酰酶抑制剂(Chidamide)、来那度胺和依托泊苷治疗难治性/复发性结外自然杀伤/T细胞淋巴瘤,鼻腔。2023年EHA。4.Jae-Cheol Jo、Misung Kim、Yunsuk Choi等人。程序性细胞死亡1和程序性细胞死亡配体1在鼻型结外NK/T细胞淋巴瘤中的表达
|
网址 |
求助人暂未提供
|
DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
其它 | Ann. Hematol. 2017, 96, 25–31. |
求助人 | |
下载 |